

Pulmonary Rehabilitation

COPD

COPD : Definition

- ❖ COPD, a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases.
- ❖ Exacerbations and comorbidities contribute to the overall severity in individual patients.

COPD

Emphysema


- * Permanent enlargement of airspaces distal to the terminal bronchioles
- * Loss of alveolar walls results in **decrease in elastic recoil**
- * Loss of the alveolar supporting structure leads to airway narrowing, which further limits airflow

Chronic bronchitis


- * Chronic productive cough for 3 months
- * Mucous gland hyperplasia
- * Damage to the endothelium impairs the mucociliary response
- * Narrowing of airway caliber and **increase in airway resistance**
- * Undamaged pulmonary capillary bed

COPD

Emphysema




Chronic bronchitis



COPD

Emphysema



Chronic bronchitis



Mechanisms Underlying Airflow Limitation in COPD

Small Airways Disease

- Airway inflammation
- Airway fibrosis, luminal plugs
- Increased airway resistance

Parenchymal Destruction

- Loss of alveolar attachments
- Decrease of elastic recoil

AIRFLOW LIMITATION


COPD : Severity

Table 1-1 Classification of COPD Severity¹¹ (Level III)

COPD stage	Severity	Post-bronchodilator spirometric values ¹¹ (Level III)	Symptoms that may be present
I	Mild	FEV ₁ /FVC < 0.70 FEV ₁ ≥ 80% predicted	Chronic cough and sputum production may be present. At this stage, the individual is usually unaware that his or her lung function is abnormal.
II	Moderate	FEV ₁ /FVC < 0.70 50% ≤ FEV ₁ < 80% predicted	Dyspnoea typically on exertion, cough and sputum production sometimes also present. This is the stage at which patients usually seek medical attention because of chronic respiratory symptoms or an exacerbation of COPD.
III	Severe	FEV ₁ /FVC < 0.70 30% ≤ FEV ₁ < 50% predicted	Greater dyspnoea, reduced exercise capacity, fatigue, and repeated exacerbations that almost always have an impact on the patient's quality of life.
IV	Very severe	FEV ₁ /FVC < 0.70 FEV ₁ < 30% predicted or FEV ₁ < 50% predicted plus chronic respiratory failure	Respiratory failure may lead to cor pulmonale with signs which include elevation of the jugular venous pressure and pitting ankle oedema. At this stage, quality of life is markedly impaired and exacerbations may be life-threatening.

FEV₁: forced expiratory volume in one second; FVC: forced vital capacity; respiratory failure: arterial partial pressure of oxygen (PaO₂) less than 8.0 kPa (60 mmHg) with or without arterial partial pressure of CO₂ (PaCO₂) greater than 6.7 kPa (50 mmHg) while breathing air at sea level.

Risk Factors for COPD



Consequences of respiratory disease

- * Peripheral muscle dysfunction
- * Respiratory muscle dysfunction
- * Nutritional abnormalities
- * Cardiac impairment
- * Psychosocial dysfunction
- * Skeletal disease

Pulmonary Rehabilitation

The bottom of the slide features a series of overlapping, wavy, light blue lines that create a sense of movement and depth, transitioning from the solid blue background above.

Definition

- * Pulmonary rehabilitation is an evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities.

Evidence Category	Sources of Evidence	Definition
A	Randomized controlled trials (RCTs). Rich body of data.	Evidence is from endpoints of well-designed RCTs that provide a consistent pattern of findings in the population for which the recommendation is made. Category A requires substantial numbers of studies involving substantial numbers of participants.
B	Randomized controlled trials. Limited body of data.	Evidence is from endpoints of intervention studies that include only a limited number of patients , posthoc or subgroup analysis of RCTs, or meta-analysis of RCTs . In general, Category B pertains when few randomized trials exist, they are small in size, they were undertaken in a population that differs from the target population of the recommendation, or the results are somewhat inconsistent.
C	Nonrandomized trials. Observational studies.	Evidence is from outcomes of uncontrolled or nonrandomized trials or from observational studies.
D	Panel consensus judgment	This category is used only in cases where the provision of some guidance was deemed valuable but the clinical literature addressing the subject was deemed insufficient to justify placement in one of the other categories. The Panel Consensus is based on clinical experience or knowledge that does not meet the above-listed criteria.

Benefits of Pulmonary Rehabilitation

- * Improves exercise capacity (Evidence A)
- * Reduces the perceived intensity of breathlessness (Evidence A)
- * Improves health-related quality of life (Evidence A)
- * Reduces the number of hospitalizations and days in the hospital (Evidence A)
- * Reduces anxiety and depression associated with COPD (Evidence A)
- * Improves recovery after hospitalization for an exacerbation (Evidence A)

Benefits of Pulmonary Rehabilitation

- * Strength and endurance training of the upper limbs improves arm function (Evidence B)
- * Benefits extend well beyond the immediate period of training (Evidence B)
- * Improves survival (Evidence B)
- * Enhances the effect of long-acting bronchodilators (Evidence B)
- * Respiratory muscle training can be beneficial, especially when combined with general exercise training (Evidence C)

Multidisciplinary Team

- * Pul. Rehab. team medical director
- * Respiratory care practitioner
- * Nurse
- * Physical therapist
- * Occupational therapist
- * Exercise physiologist
- * Psychologist
- * Vocational counselor
- * Recreational therapist
- * Social worker
- * Nutritionist

Comprehensive Pulmonary Rehabilitation

- * Exercise training
- * Chest physical therapy and breathing techniques
- * Education
- * Nutritional counseling
- * Psychosocial/behavioral intervention
- * Outcome assessment



Exercise training


Mechanisms for morbidities

- * Deconditioning
- * Malnutrition
- * Effects of hypoxemia
- * Steroid myopathy or critically-ill neuropathy
- * Diaphragmatic fatigue
- * Frequent hospitalizations
- * Effects of various medications
- * Psychosocial dysfunction resulting from anxiety, depression, guilt, dependency and sleep disturbance.

Evidence of Skeletal Muscle Dysfunction in COPD

- * Lactic acidosis threshold is low.
- * Intramuscular fall in pH with exercise is accentuated.
- * Muscle aerobic enzymes are low.
- * Oxygen uptake kinetics are slow.
- * Muscle mass is low.

Effects on Skeletal Muscle

- * Systemic inflammatory mediators accelerate **muscle protein turnover**
- * Malnutrition  reduced protein intake leads to **muscle breakdown** (type II fibers)
- * Malnutrition also contributes to **reduced muscle enzyme capacity**
- * Hypoxemia reduces oxygen delivery to all the organs of the body
- * The respiratory-muscles “steal” blood away from skeletal muscles, which further compromises systemic muscle function.

Effects on Skeletal Muscle

- * Impair mitochondrial oxygen utilization, which produces muscle-cell hypoxia and thus a **conversion to anaerobic metabolism at low levels of exercise**
- * This leads to **lactate accumulation** and earlier fatigability of the muscles.

Respiratory VS Skeletal Muscles

- * In limb muscles, especially lower-extremity limb muscles, muscle weakness and respiratory insufficiency lead to inactivity and **chronic underloading** of the muscles.
- * In limb muscles, underloading leads to **less muscle mass**, especially **decreases in the type I fibers**. This reduces the oxidative capacity of the muscles and makes them more prone to fatigue.

Respiratory VS Skeletal Muscles

- * In contrast, respiratory muscles have to deal with an increased work to breathe and are thus **chronically overloaded**.
- * Structurally, diaphragmatic sarcomeres become shorter to adapt to the new shorter resting length.
- * More oxidative or type I sarcomeres also develop, and these increase endurance capabilities

diaphragm

Table 1. Properties of Muscle-Fiber Types

Muscle-Fiber Type	Description	Metabolism	Myoglobin/mitochondria	Function
I	Slow, fatigue-resistant	Oxidative	Rich, "red"	Standing Quiet breathing
Ila*	Fast, fatigue-resistant	Oxidative/glycolytic	Mixed	Walking Hyperventilating
Ilb*	Fast, fatigable	Glycolytic	Low, "white"	Jumping Coughing

* An intermediate Type Iix fiber with fast twitch features and intermediate fatigability has also been described.

Exercise Limitation

- * Gas exchange abnormalities
- * Dynamic lung hyperinflation
- * Insufficient energy supply to the peripheral and respiratory muscles
- * Morphological alterations in leg and diaphragm
- * Scand J Med Sci Sports 2009; 19: 865-870
- * Chest 2005; 128: 651-656

Implementing an Exercise Training Program

- * Endurance training
- * Strength training
- * Inspiratory muscle training
- * Electrical muscle stimulation
- * Whole body vibration training : improve exercise capacity, muscle force and quality of life (*Am J Respir Crit Care Med* 2011; 183: A3968, *Respir Med* 2012; 106: 75-83)

Endurance Training

- * Most common
- * Improve aerobic exercise
- * improve quality of life
- * Change of muscle fiber morphology and typology
- * **High-intensity endurance training** induces greater physiological benefits than lower intensity exercise
- * Continuous versus interval training

Endurance Training

TABLE 2 Practical recommendations for the implementation of continuous and interval endurance training programmes

Continuous endurance training		Interval endurance training
Frequency	3–4 days-week ⁻¹	3–4 days-week ⁻¹
Mode	Continuous	Interval modes: 30 s of exercise, 30 s of rest or 20 s of exercise, 40 s of rest
Intensity	Initially 60–70% of PWR Increase work load by 5–10% as tolerated	Initially 80–100% of PWR for the first three to four sessions Increase work load by 5–10% as tolerated
Duration	Progressively try to reach ~80–90% of baseline PWR Initially 10–15 min for the first three to four sessions Progressively increase exercise duration to 30–40 min	Progressively try to reach ~150% of baseline PWR Initially 15–20 min for the first three to four sessions Progressively increase exercise duration to 45–60 min (including resting time)
Perceived exertion	Try to aim for a perceived exertion on the 10-point Borg scale of 4 to 6	Try to aim for a perceived exertion on the 10-point Borg scale of 4 to 6
Breathing technique	Suggest pursed-lip breathing or the use of PEP devices to prevent dynamic hyperinflation and to reduce breathing frequency	Suggest pursed-lip breathing or the use of PEP devices to prevent dynamic hyperinflation and to reduce breathing frequency

PWR: peak work rate; PEP: positive expiratory pressure. Adapted from [30].

Strength Training

TABLE 4 Practical recommendations for the implementation of strength training	
Frequency	2–3 days-week ¹
Objective	Targeting for local muscular exhaustion within a given number of repetitions for major muscle groups of upper and lower extremities
Mode	Two to four sets of six to 12 repetitions
Intensity	50–85% of one repetitive maximum as a reference point Increase work load by 2–10% if one to two repetitions over the desired number are possible on two consecutive training sessions
Speed	Moderate (1–2 s concentric and 1–2 s eccentric)
Data from [53].	




Fig. 4. Changes in exercise-test results after exercise rehabilitation in patients with chronic obstructive pulmonary disease. The exercise tests were performed before and after the exercise rehabilitation, using the same exercise work load, so decreases represent improved function (less lactate development), lower ventilation requirement, lower oxygen need, lower carbon-dioxide production, and lower heart-rate requirement. Patients in the left panel underwent a high-intensity exercise program; patients in the right panel underwent a less intense exercise program. Though both the exercise programs improved function, the high-intensity program produced a greater effect. (From Reference 45, with permission.)



Chest Physical Therapy and Breathing Techniques

Chest Physical Therapy and Breathing Techniques

- * Pursed-lip breathing relieves dyspnea by increasing expiratory airway pressure, thereby inhibiting dynamic expiratory airway collapse.
- * Pursed-lip breathing shifts a major portion of the inspiratory work of breathing from the diaphragm to the ribcage muscles.


3 Major Breathing Techniques

- * **Pursed-lip breathing** relieves dyspnea by increasing expiratory airway pressure, thereby inhibiting dynamic expiratory airway collapse.
- * Pursed-lip breathing shifts a major portion of the inspiratory work of breathing from the diaphragm to the ribcage muscles.
- * **Posture techniques** : leaning-forward
- * **Diaphragmatic breathing**



Education

Smoking Cessation



Nutrition

- * Weight loss is a poor prognostic indicator.
- * A reduction in BMI is an independent risk factor for mortality in COPD patients.

Nutrition

- * Choose easy to chew foods
- * Eat 6 small meals instead of 3 regular ones.
- * If loss of appetite, eat high calorie foods first or try liquid supplements e.g. Ensure
- * Avoid or eat small portions of foods that cause gas.
- * Eat slowly
- * Clear the throat or cough gently every so often to clear your airway of saliva and food
- * Drink fluids carefully, avoid drinking a lot of fluids with your meal.
- * Use oxygen as prescribed.

Travel

- * Plane : patients with COPD and LTOT can achieve to maintain an-in-flight PaO₂ of at least 50 mmHg by supplementary oxygen at 3L/min by nasal cannula.
- * Resting PaO₂ at sea level >70 mmHg : likely to be safe to fly without supplementary oxygen



OUTCOME

Outcome Measures

- * Lung function
- * Exercise capacity
- * Dyspnea
- * Health status

Lung Function : FEV1

- * Indicate disease progression
- * Do not always correlate with clinically relevant outcomes such as dyspnea, health status, and exercise capacity

Exercise capacity : 6MWT

Strength

- * Simple to perform, well tolerated
- * Reflects everyday life-like activity
- * Correlate with lung function, health status, and maximal VQ2 (Brown CD, Wise RA: Field tests of exercise in COPD: The six-minute walk test and the shuttle walk test. **COPD 2007, 4:217-223.**)
- * Predictive for mortality (Cote CG, Casanova C, Mañ JM, Lopez MV, Pinto-Plata V, De Oca MM, Dordelly LJ, Nekach H, Celli BR: Validation and comparison of reference equations for the 6-min walk distance test. **Eur Respir J 2008, 31:571-578.**)

Limitations

- * Patient's motivation
- * Spatial requirements
- * Personnel and time consuming
- * Frequently change direction
- * Learning effect

Dyspnea

Table 2: Dyspnoea measurement scales

	Type of scale	Type of stimulus	Items	Administration
BDI/TDI	multi-dimensional	everyday activities	8/9	interview
MRC-Scale	uni-dimensional	everyday activities	1	self-administered by patient
Borg-Scale	uni-dimensional	under exertion	1	self-administered by patient

BDI: Baseline Dyspnoea Index; TDI: Transition Dyspnoea Index; MRC: Medical Research Council.

BASELINE DYSPNEA INDEX (BDI)

Baseline Functional Impairment

Grade 4	<i>No Impairment</i>	Able to carry out usual activities and occupation without shortness of breath.
Grade 3	<i>Slight Impairment</i>	Distinct impairment in at least one activity but no activities completely abandoned . Reduction, in activity at work or in usual activities, that seems slight or not clearly caused by shortness of breath.
Grade 2	<i>Moderate Impairment</i>	Subject has changed jobs and/or has abandoned at least one usual activity due to shortness of breath.
Grade 1	<i>Severe Impairment</i>	Subject unable to work or has given up most or all usual activities due to shortness of breath.
Grade 0	<i>Very Severe Impairment</i>	Unable to work and has given up most or all usual activities due to shortness of breath.
W	<i>Amount Uncertain</i>	Subject is impaired due to shortness of breath, but amount cannot be specified. Details are not sufficient to allow impairment to be categorised.
X	<i>Unknown</i>	Information unavailable regarding impairment.
Y	<i>Impaired for Reasons Other than Shortness of Breath</i>	For example, musculoskeletal problem or chest pain.

BASELINE DYSPNEA INDEX (BDI)

Baseline Magnitude of Task

Grade 4	<i>Extraordinary</i>	Becomes short of breath only with extraordinary activity such as carrying very heavy loads on the level, lighter loads uphill, or running. No shortness of breath with ordinary tasks.
Grade 3	<i>Major</i>	Becomes short of breath only with such major activities as walking up a steep hill, climbing more than three flights of stairs , or carrying a moderate load on the level.
Grade 2	<i>Moderate</i>	Becomes short of breath with moderate or average tasks such as walking up a gradual hill, climbing fewer than three flights of stairs , or carrying a light load on the level.
Grade 1	<i>light</i>	Becomes short of breath with light activities such as talking, on the level , washing, or standing.
Grade 0	<i>No Task</i>	Becomes short of breath at rest, while sitting, or lying down.
W	<i>Amount Uncertain</i>	Subject's ability to perform tasks is impaired due to shortness of breath, but amount cannot be specified. Details are not sufficient to allow impairment to be categorised.
X	<i>Unknown</i>	Information unavailable regarding limitation of magnitude of task.
Y	<i>Impaired for Reasons Other than Shortness of Breath</i>	For example, musculoskeletal problem or chest pain.

BASELINE DYSPNEA INDEX (BDI)

Baseline Magnitude of Effort

Grade 4	<i>Extraordinary</i>	Becomes short of breath only with the greatest imaginable effort. No shortness of breath with ordinary effort.
Grade 3	<i>Major</i>	Becomes short of breath with effort distinctly submaximal, but of major proportion. Tasks performed without pause unless the task requires extraordinary effort that may be performed with pauses.
Grade 2	<i>Moderate</i>	Becomes short of breath with moderate effort. Tasks performed with occasional pauses and requiring longer to complete than the average person.
Grade 1	<i>light</i>	Becomes short of breath with little effort. Tasks performed with little effort or more difficult tasks performed with frequent pauses and requiring 50-100% longer to complete than the average person might require.
Grade 0	<i>No Task</i>	Becomes short of breath at rest, while sitting, or lying down.
W	<i>Amount Uncertain</i>	Subject's exertional ability is impaired due to shortness of breath, but amount cannot be specified. Details are not sufficient to allow impairment to be categorised.
X	<i>Unknown</i>	Information unavailable regarding limitation of effort.
Y	<i>Impaired for Reasons Other than Shortness of Breath</i>	For example, musculoskeletal problems or chest pain.

Modified MRC (mMRC) Questionnaire

Table 1. Modified Medical Research Council (mMRC) Questionnaire for Assessing the Severity of Breathlessness

Please tick in the box that applies to you (1 box only)

mMRC Grade 0	I only get breathless with strenuous exercise.	<input type="checkbox"/>
mMRC Grade 1	I get short of breath when hurrying on the level or walking up a slight hill.	<input type="checkbox"/>
mMRC Grade 2	I walk slower than people of the same age on the level because of breathlessness, or I have to stop for breath when walking on my own pace on the level.	<input type="checkbox"/>
mMRC Grade 3	I stop for breath after walking about 100 meters or after a few minutes on the level.	<input type="checkbox"/>
mMRC Grade 4	I am too breathless to leave the house or I am breathless when dressing or undressing.	<input type="checkbox"/>

Source: Reprinted with permission from the *Global Strategy for Diagnosis, Management, and Prevention of COPD*, www.goldcopd.org.⁴

Table 3

Modified Borg Scale

0	(Dyspnea) NONE
0.5	(Dyspnea) EXTREMELY MILD
1	(Dyspnea) VERY MILD
2	(Dyspnea) MILD
3	(Dyspnea) MODERATE
4	(Dyspnea) INTENSE
5	(Dyspnea) RATHER INTENSE
6	
7	(Dyspnea) VERY INTENSE
8	
9	(Dyspnea) ALMOST UNBEARABLE
10	(Dyspnea) UNBEARABLE

From [\[37\]](#), mod.

COPD Assessment Test

Your name:

Today's date:



How is your COPD? Take the COPD Assessment Test™ (CAT)

This questionnaire will help you and your healthcare professional measure the impact COPD (Chronic Obstructive Pulmonary Disease) is having on your wellbeing and daily life. Your answers, and test score, can be used by you and your healthcare professional to help improve the management of your COPD and get the greatest benefit from treatment.

For each item below, place a mark (X) in the box that best describes you currently. Be sure to only select one response for each question.

Example: I am very happy 0 ☒ 1 2 3 4 5 I am very sad

		SCORE
I never cough	0 1 2 3 4 5 I cough all the time	
I have no phlegm (mucus) in my chest at all	0 1 2 3 4 5 My chest is completely full of phlegm (mucus)	
My chest does not feel tight at all	0 1 2 3 4 5 My chest feels very tight	
When I walk up a hill or one flight of stairs I am not breathless	0 1 2 3 4 5 When I walk up a hill or one flight of stairs I am very breathless	
I am not limited doing any activities at home	0 1 2 3 4 5 I am very limited doing activities at home	
I am confident leaving my home despite my lung condition	0 1 2 3 4 5 I am not at all confident leaving my home because of my lung condition	
I sleep soundly	0 1 2 3 4 5 I don't sleep soundly because of my lung condition	
I have lots of energy	0 1 2 3 4 5 I have no energy at all	
		TOTAL SCORE

COPD Assessment Test and the CAT logo is a trade mark of the GlaxoSmithKline group of companies.

© 2009 GlaxoSmithKline group of companies. All rights reserved.

Last Updated: February 24, 2012

CCQ

Patient number: _____
Date: _____

CLINICAL COPD QUESTIONNAIRE

Please circle the number of the response that best describes how you have been feeling during the **past week**.
(Only **one** response for each question).

On average, during the past week, how often did you feel:	never	hardly ever	a few times	several times	many times	a great many times	almost all the time
1. Short of breath at rest?	0	1	2	3	4	5	6
2. Short of breath doing physical activities?	0	1	2	3	4	5	6
3. Concerned about getting a cold or your breathing getting worse?	0	1	2	3	4	5	6
4. Depressed (down) because of your breathing problems?	0	1	2	3	4	5	6
In general, during the past week, how much of the time:							
5. Did you cough?	0	1	2	3	4	5	6
6. Did you produce phlegm?	0	1	2	3	4	5	6
On average, during the past week, how limited were you in these activities because of your breathing problems:	not limited at all	very slightly limited	slightly limited	moderately limited	very limited	extremely limited	totally limited /or unable to do
7. Strenuous physical activities (such as climbing stairs, hurrying, doing sports)?	0	1	2	3	4	5	6
8. Moderate physical activities (such as walking, housework, carrying things)?	0	1	2	3	4	5	6
9. Daily activities at home (such as dressing, washing yourself)?	0	1	2	3	4	5	6
10. Social activities (such as talking, being with children, visiting friends/relatives)?	0	1	2	3	4	5	6

Follow-up

- * History and physical examination
- * Lung function : post-bronchodilator spirometry
- * Assessment of exercise capacity
- * Measurement of health status and impact of dyspnea
e.g. MMRC, CAT, BDI
- * Assessment of inspiratory and expiratory muscle strength and lower limb strength in patients who suffer from muscle wasting.



COPD and Comorbidities

COPD/CVD Relationship

- * COPD patients were nearly 5 times more likely to have CVD than those without COPD (Thorax 2010; 65:956)
- * Every 10% decrease in FEV_1 , cardiovascular mortality increases by 28% (Proc Am Thorac Soc 2005; 2:8)
- * In patients with concomitant severe COPD and CAD : **nonpharmacologic therapies** eg. smoking cessation, pulmonary rehabilitation, vaccination against influenza and pneumococcus, supplemental oxygen are indicated to reduce symptoms, improve quality of life and prevent exacerbations.

Indications for LTOT (long term oxygen therapy)

- * > 15 hours per day.
- * LTOT improves survival 2-fold or more in hypoxemic patients with COPD.
- * $\text{PaO}_2 \leq 55$ mmHg or $\text{SaO}_2 \leq 88\%$ during rest (**Evidence B**)
- * PaO_2 56-59 mmHg or $\text{SaO}_2 > 88\%$ combined with evidence of pulmonary hypertension, cor pulmonale, right heart failure or polycythemia ($\text{Hct} > 55\%$) (Evidence D)
- * $\text{PaO}_2 > 60$ mmHg or $\text{SaO}_2 > 90\%$ with significant coronary heart disease or active cardiac ischemia.

Supplemental Oxygen

- * COPD who are not hypoxemic at rest, worsens during exertion
- * During exercise, oxygen supplementation can:
 - improve peripheral muscle oxygenation
 - reduce dyspnea
 - improve exercise tolerance
 - prevent increases in pulmonary artery pressure

Prognosis : 4 Factors

- * **BMI** : greater than 21 = 0 points; less than 21 = 1 point
- * **FEV₁** : greater than 65% = 0 points
 - 50-64% = 1
 - 36-49% = 2
 - < 35% = 3
- * **MMRC**
- * **6MWT** :>350 meters = 0 points
 - 250-349 meters = 1
 - 150-249 meters = 2
 - < 149 meters = 3

BODE Index for COPD

The BODE Index is a composite marker of disease taking into consideration the systemic nature of COPD (Celli et al., 2004).

Scoring the BODE Index

	0	1	2	3
FEV ₁ % pred	≥65	50-64	36-49	≤35
6MWD (m)	≥350	250-349	150-249	≤149
MMRC	0-1	2	3	4
BMI (kg.m ⁻²)	>21	≤21		

Total BODE Index score = 0 to 10 units

(FEV₁% pred = predicted amount as a percentage of the forced expiratory lung volume in one second; 6MWD = six minute walking distance; MMRC = modified medical research council dyspnea scale; BMI = body mass index)

Prognosis : 4-year survival

- * 0-2 points = 80%
- * 3-4 points = 67%
- * 5-6 points = 57%
- * 7-10 points = 18%

Global Initiative for Chronic
Obstructive
Lung
Disease



**GLOBAL STRATEGY FOR THE DIAGNOSIS,
MANAGEMENT, AND PREVENTION OF
CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

Updated 2013
